Aphea.Bio secures € 14 million Series B financing to further
develop its next generation agricultural biologicals
New funding confirms Aphea.Bio's frontrunner position in sustainable and innovative agriculture
Aphea.Bio, a Belgium-based agtech startup, announced today that it secured a € 14 million Series B
round led by Astanor Ventures and joined by current shareholders V-Bio Ventures, Agri Investment
Fund, PMV, Vives Fund, VIB, Qbic II and Gemma Frisius Fund.
This funding further strengthens Aphea.Bio's plans to advance its biostimulant and biofungicide
research and development programs towards submission of the regulatory dossier and to support
the launch of the company's first products. This new round of funding will also support expanded
research and development in the areas of bioinsecticides and bioherbicides. With its broad pipeline,
Aphea.Bio sets course to become the 'one-stop-shop' for biological product development.
"Astanor Ventures is the perfect lead investor in Aphea.Bio's Series B funding, said Isabel
Vercauteren, CEO of Aphea.Bio". "We both share the same ambition of making an impact on
modern agriculture and to move towards a more healthy and sustainable food system".
Hendrik Van Asbroeck, Partner at Astanor Ventures, said: "Astanor's core thesis, a healthy food
system starts from the soil, is fully in line with the strategy of Aphea.Bio. Toxicity of chemical
pesticides and the urgent need to restore the soil microbiome argue in favor of new innovative
players such as Aphea.Bio. We are certain that with such an outstanding team and technology,
Aphea.Bio will pave the way towards a more sustainable agrifood sector."
Steven Vandenabeele, CSO at Aphea.Bio added: "We succeed in using microorganisms via seed
treatment as a growth promoter in wheat, achieving significantly higher yields under reduced
fertilizer regimes. Besides that, our field trial campaigns indicate that our sprayable applications to
protect wheat against the economically most important fungal diseases offer a sustainable
alternative to chemical pesticides."
Johan De Saegher, chairman of the board, said: "Aphea.Bio's products will provide disruptive full-
fledged bio-based s0lutions to the farmers to control diseases and pests and to use more efficiently
fertilizers in the main food crops. With its biostimulant and biopesticides product concepts,
Aphea.Bio anticipates the vision of using at least 20% less fertilizers and halving the use of
chemical pesticides by 2030, as outlined in the Farm-to-Fork strategy, a cornerstone of the
European Green Deal."
Encouraged by promising data, propelled by an outstanding team, motivated by the European Green
Deal ambitions and backed by a solid consortium of investors, Aphea.Bio is now up for the further
development and scale up of the most promising products. Isabel Vercauteren concluded "We are
thrilled to bring the company to this next important phase towards launching our products to the
EuroChem and Aphea.Bio launch R&D collaboration
EuroChem Group AG ("EuroChem" or the "Group"), a leading global fertilizer producer, and Belgium-based biotechnology company Aphea.Bio announce the signing of a research and development agreement.
The agreement will see the two companies collaborate on the development of next-generation fertilizer technologies designed to significantly boost the take-up of key nutrients by plants. The research will utilize
data and samples from scientific field trials at 10 different locations all over Europe.
EuroChem, which with the recent launch of potash mining became one of just three companies in the world to produce fertilizers in all three primary nutrient categories, is developing enhanced efficiency and
slow-release fertilizers that are optimized for different soil conditions. These help improve yields and enable farmers to grow more crops from the same amount of land, vital as the world's population continues
to grow. The increased nutrient uptake also minimizes losses to the environment.
Dr Thomas Mannheim (head of Global R&D for Premium Products EuroChem):
"This agreement will further strengthen EuroChem's commitment to investing in innovation. We are committed to helping farmers optimize resource use and enabling them to enhance their yields and economic
Dr. Isabel Vercauteren (CEO Aphea.Bio):
"We are delighted to have signed EuroChem as our first commercial partner. EuroChem has deep expertise in the mineral fertilizer sector and we look forward to a long and fruitful collaboration together."
Commercial terms of the agreement between the two companies have not been disclosed.
Aphea.Bio aims at leading position in next generation agricultural biologicals
New VIB spin-off launches with 9 million euros in funding
VIB, Ghent University and KU Leuven have launched a new spin-off: Aphea.Bio. This new company will develop sustainable agricultural products based on natural microorganisms to increase crop yields and to
protect them against specific fungal diseases. Thanks to a successful Series A financing round and an R&D grant approved by Flanders Innovation & Entrepreneurship (VLAIO), Aphea.Bio is now backed by 9 million
euros of funding, giving it a clear shot at a leading position in the fast-emerging market of biopesticides and biostimulants. Headquartered in Ghent, Belgium, Aphea.Bio will be led by CEO Dr. Isabel
Vercauteren and CSO Dr. Steven Vandenabeele.
The VIB spin-off pulls together resources and expertise in plant-bacteria interactions of the lab of prof. Sofie Goormachtig (VIB-Ghent University) and microbiome know-how contributed by the group of prof. Jeroen
Raes (VIB-KU Leuven).
Superior microorganisms for sustainable agriculture
Aphea.Bio will develop next generation 'biopesticides' based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition,
the company will develop novel 'biostimulants', i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.
Dr. Isabel Vercauteren (CEO Aphea.Bio):
"This financing puts us in an excellent position to develop new and superior agricultural products based on naturally occurring microorganisms that have a growth promoting or protective effect on the plant.
We distinguish ourselves in this growing and competitive market through our unique technology platform. A large number of microorganisms that coexist with plants haven't been isolated so far, yet our
expertise allows us to exploit this untapped microbial space. Our applications are focused on staple crops such as wheat, barley and maize, because they offer the most valuable European and global market
Successful funding round
In total, Aphea.Bio has raised 7.7 million euros in capital. The series A financing round was led by V-Bio Ventures and was joined by a broad syndicate of investors including PMV, Agri Investment Fund, VIVES,
Qbic II, Gemma Frisius Fund KU Leuven, Group De Ceuster and VIB itself.
Furthermore, Flanders Innovation & Entrepreneurship (VLAIO) has approved an R&D grant worth 1.3 million euros, bringing Aphea.Bio's total financial resources to 9 million euros.
Dr. Willem Broekaert (Managing Partner V-Bio Ventures):
"We are highly pleased to have built a strong investor consortium that provides the necessary financial backing for this innovative start-up company. This group of investors also brings along a unique network
through their relationships with scientific institutions and key players in the agricultural sector."
Dr. Johan Cardoen (Managing Director VIB):
"This is a great example of the vital impact of basic plant research on sustainable agriculture. All stakeholders are committed to propel Aphea.Bio into a leading position in the agro-biologicals sector. The
last piece of the puzzle has been laid to make this company successful: there is now a strong team in place composed of passionate scientists with academic as well as strong industry background."